Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $157,000.

  • Niagen Bioscience's Depreciation & Amortization (CF) fell 4.27% to $157,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $624,000, marking a year-over-year decrease of 9.43%. This contributed to the annual value of $663,000 for FY2024, which is 23.79% down from last year.
  • Latest data reveals that Niagen Bioscience reported Depreciation & Amortization (CF) of $157,000 as of Q3 2025, which was down 0.63% from $158,000 recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Depreciation & Amortization (CF) peaked at $235,000 during Q3 2022, and registered a low of $151,000 during Q4 2024.
  • For the 3-year period, Niagen Bioscience's Depreciation & Amortization (CF) averaged around $182,364, with its median value being $170,000 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first increased by 13.43% in 2023, then fell by 29.61% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Depreciation & Amortization (CF) stood at $211,000 in 2021, then grew by 4.74% to $221,000 in 2022, then dropped by 19.91% to $177,000 in 2023, then dropped by 14.69% to $151,000 in 2024, then decreased by 4.27% to $157,000 in 2025.
  • Its Depreciation & Amortization (CF) was $157,000 in Q3 2025, compared to $158,000 in Q2 2025 and $158,000 in Q1 2025.